Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development

from Venture Capital Access Online: Latest Venture Capital and Private Equity News http://bit.ly/2DnlukT
via IFTTT